Algernon Pharmaceuticals (XCNQ:AGN) Total Assets : C$3.66 Mil (As of Nov. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Total Assets?

Algernon Pharmaceuticals's Total Assets for the quarter that ended in Nov. 2024 was C$3.66 Mil.

During the past 12 months, Algernon Pharmaceuticals's average Total Assets Growth Rate was -15.00% per year. During the past 3 years, the average Total Assets Growth Rate was -24.30% per year. During the past 5 years, the average Total Assets Growth Rate was -10.20% per year.

During the past 10 years, Algernon Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 456.10%. The lowest was -24.30%. And the median was 96.60%.

Total Assets is connected with ROA %. Algernon Pharmaceuticals's annualized ROA % for the quarter that ended in Nov. 2024 was -40.11%. Total Assets is also linked to Revenue through Asset Turnover. Algernon Pharmaceuticals's Asset Turnover for the quarter that ended in Nov. 2024 was 0.00.

Algernon Pharmaceuticals Total Assets Historical Data

The historical data trend for Algernon Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals Total Assets Chart

Algernon Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Total Assets

Get a 7-Day Free Trial

12.82

10.14

8.14

4.19

3.94

Algernon Pharmaceuticals Quarterly Data
	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24
Total Assets	Get a 7-Day Free Trial															3.95	3.95	3.89	3.94	3.66

Algernon Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Algernon Pharmaceuticals's Total Assets for the fiscal year that ended in Aug. 2024 is calculated as

Total Assets	=	Total Equity (A: Aug. 2024 )	+	Total Liabilities (A: Aug. 2024 )
	=	2.169	+	1.775
	=	3.94

Algernon Pharmaceuticals's Total Assets for the quarter that ended in Nov. 2024 is calculated as

Total Assets	=	Total Equity (Q: Nov. 2024 )	+	Total Liabilities (Q: Nov. 2024 )
	=	1.788	+	1.867
	=	3.66

Algernon Pharmaceuticals (XCNQ:AGN) Total Assets Explanation

Total Assets is connected with ROA %.

Algernon Pharmaceuticals's annualized ROA % for the quarter that ended in Nov. 2024 is

ROA %	=	Net Income (Q: Nov. 2024 )	/	( (Total Assets (Q: Aug. 2024 )	+	Total Assets (Q: Nov. 2024 ))	/ count )
	=	-1.524	/	( (3.944	+	3.655)	/ 2 )
	=	-1.524	/	3.7995
	=	-40.11 %

Note: The Net Income data used here is four times the quarterly (Nov. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Algernon Pharmaceuticals's Asset Turnover for the quarter that ended in Nov. 2024 is

	Asset Turnover
=	Revenue (Q: Nov. 2024 )	/	( (Total Assets (Q: Aug. 2024 )	+	Total Assets (Q: Nov. 2024 ))	/ count )
=	0	/	( (3.944	+	3.655)	/ 2 )
=	0	/	3.7995
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Algernon Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Algernon Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (XCNQ:AGN) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

AGNPF:USA AGW0:Germany

Address

601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2

Website

https://www.algernonpharmaceuticals.com

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis, and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.

Executives

Christopher Moreau	Director, Senior Officer
Christopher Scott Bryan	Senior Officer
James Kinley	Senior Officer
Harry J.f. Bloomfield	Director
Rajpaul Attariwala	Director
Mark Williams	Director
Howard Gutman	Director
Michael Sadhra	Senior Officer
Kulwant Malhi	10% Security Holder

Algernon Pharmaceuticals Headlines

No Headlines